

Press release

Contact:

Torben Jörgensen, President and CEO

Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

Biotage AB

Kungsgatan 76

SE-753 18 Uppsala

Tel+46 18 56 59 00

www.biotage.com

Uppsala May 24 , 2010

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting's resolution to authorize the board to decide on the acquisition and sale of the company's own shares.

At the Annual General Meeting held on 29 April 2010, the board was authorized to decide on the acquisition and sale of the company's own shares up and until the forthcoming Annual General Meeting. The shares acquired may not exceed 10 per cent of the total number of outstanding Biotage shares at any time. The purpose of the repurchase program is to give the board a wider freedom of action in the work with the company's capital structure and thereby improve shareholder value. Acquisition and sale of shares will take place on the NASDAQ OMX Stockholm at a price within the price interval at any time recorded. Biotage currently own 1,970,230 Biotage shares.

This is information that Biotage AB (publ) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on May 24, 2010 at 8.30am CET

About Biotage

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 245 employees and had sales of 394.1 MSEK in 2009. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com